Evidence map›Paper›PMID 27465145›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2016

Characterisation of Clostridium difficile strains isolated from Groote Schuur Hospital, Cape Town, South Africa.

B Kullin, T Brock, N Rajabally, F Anwar, G Vedantam, S Reid, V Abratt

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Insights into the Evolving Epidemiology ofAntibiotics (Basel, Switzerland) · 2023
    Review
  2. Characterization of community-acquiredFrontiers in microbiology · 2023
    Article
  3. Review
  4. Antibiotic Resistance and Biofilm Production Capacity inFrontiers in cellular and infection microbiology · 2021
    Article
  5. Emerging microbes & infections · 2019
    Review
  6. Review
  7. African journal of laboratory medicine · 2018
    Article
  8. Review
  9. Article
  10. Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

B KullinDepartment of Molecular and Cell Biology, University of Cape Town, Rondebosch Cape Town, 7700, South Africa.
T BrockDepartment of Molecular and Cell Biology, University of Cape Town, Rondebosch Cape Town, 7700, South Africa.
N RajaballyDepartment of Medicine, Division of Gastroenterology, University of Cape Town, Cape Town, South Africa.
F AnwarSchool of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AR, USA.
G VedantamSchool of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AR, USA.
S ReidDepartment of Molecular and Cell Biology, University of Cape Town, Rondebosch Cape Town, 7700, South Africa.
V AbrattDepartment of Molecular and Cell Biology, University of Cape Town, Rondebosch Cape Town, 7700, South Africa. valerie.abratt@uct.ac.za.ORCID http://orcid.org/0000-0003-4631-3355
University of Cape Town · ZAUniversity of Arizona · US

Funding

BLRD VA I01 BX001183
6 · The paper itself

Abstract

The C. difficile infection rate in South Africa is concerning. Many strains previously isolated from diarrhetic patients at Groote Schuur Hospital were ribotype 017. This study further characterised these strains with respect to their clonal relationships, antibiotic susceptibility, toxin production and various attributes impacting on pathogen colonisation. Multilocus variable-number tandem-repeat analysis (MLVA) was used to characterise all C. difficile isolates. Antibiotic susceptibility was determined by E-test and PCR-based analysis of the ermB, gyrA and gyrB genes. Auto-aggregation of cells was measured in broth, and biofilm formation observed in 24-well plates. Toxins were measured using the Wampole C DIFF TOX A/B II kit. Most isolates belonged to the ribotype 017 group. Identical MLVA types occurred in different wards over time, and several patients were infected with identical strains. All isolates were susceptible to vancomycin and metronidazole, but some ribotype 017 isolates showed reduced metronidazole susceptibility (≥2 mg l(-1)). Sixty-nine percent of ribotype 017 isolates were resistant to moxifloxacin, and 94 % to erythromycin, compared to 0 % and 17 % resistance, respectively, in non-ribotype 017 isolates. The ermB gene and mutations in the gyrA and/or gyrB genes were linked to erythromycin and moxifloxacin resistance, respectively. Ribotype 017 isolates auto-aggregated more strongly than other isolates and produced lower levels of the TcdB toxin than a reference strain. Certain strains produced strong biofilms. Patient-to-patient transfer and unique infection events could cause the predominance of ribotype 017 strains in the cohort. Multi-drug resistant strains are a potential reservoir for future infections.

Indexed as

Anti-Bacterial AgentsBacterial AdhesionBacterial ToxinsBiofilmsClostridioides difficileClostridium InfectionsDiarrheaDisk Diffusion Antimicrobial TestsDNA GyraseGenotypeHospitalsHumansPilot ProjectsPolymerase Chain ReactionRibotypingSouth AfricaAnti-Bacterial AgentsBacterial ToxinsDNA Gyrase

Identifiers

PMID27465145
OpenAlexW2492508773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.